JP4101756B2 - ５−メトキシ−８−アリール−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン誘導体 - Google Patents

５−メトキシ−８−アリール−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン誘導体 Download PDF

Info

Publication number
JP4101756B2
JP4101756B2 JP2003534428A JP2003534428A JP4101756B2 JP 4101756 B2 JP4101756 B2 JP 4101756B2 JP 2003534428 A JP2003534428 A JP 2003534428A JP 2003534428 A JP2003534428 A JP 2003534428A JP 4101756 B2 JP4101756 B2 JP 4101756B2
Authority
JP
Japan
Prior art keywords
compound
methoxy
formula
phenyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003534428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508954A (ja
JP2005508954A5 (enExample
Inventor
ネッテコフェン，マサイアス・ハインリヒ
シュミット，セバスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2005508954A publication Critical patent/JP2005508954A/ja
Publication of JP2005508954A5 publication Critical patent/JP2005508954A5/ja
Application granted granted Critical
Publication of JP4101756B2 publication Critical patent/JP4101756B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003534428A 2001-10-08 2002-09-28 ５−メトキシ−８−アリール−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン誘導体 Expired - Fee Related JP4101756B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01123949 2001-10-08
PCT/EP2002/010917 WO2003031445A1 (en) 2001-10-08 2002-09-28 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists

Publications (3)

Publication Number Publication Date
JP2005508954A JP2005508954A (ja) 2005-04-07
JP2005508954A5 JP2005508954A5 (enExample) 2005-12-22
JP4101756B2 true JP4101756B2 (ja) 2008-06-18

Family

ID=8178877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003534428A Expired - Fee Related JP4101756B2 (ja) 2001-10-08 2002-09-28 ５−メトキシ−８−アリール−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン誘導体

Country Status (16)

Country Link
US (1) US6693116B2 (enExample)
EP (1) EP1436292B1 (enExample)
JP (1) JP4101756B2 (enExample)
KR (1) KR100604407B1 (enExample)
CN (1) CN1254475C (enExample)
AR (1) AR036735A1 (enExample)
AT (1) ATE338043T1 (enExample)
AU (1) AU2002338827B2 (enExample)
BR (1) BR0213177A (enExample)
CA (1) CA2462801A1 (enExample)
DE (1) DE60214408T2 (enExample)
ES (1) ES2269772T3 (enExample)
MX (1) MXPA04003278A (enExample)
PL (1) PL370565A1 (enExample)
RU (1) RU2298009C2 (enExample)
WO (1) WO2003031445A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1830978B (zh) * 2005-03-07 2010-06-16 中国人民解放军军事医学科学院毒物药物研究所 吡唑并[4,3-c]喹啉-3-酮化合物、其制备方法及其应用
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0910021A2 (pt) * 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
RU2544011C2 (ru) 2008-12-19 2015-03-10 Лео Фарма А/С Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
BR112015000507A2 (pt) * 2012-07-12 2017-06-27 Chiesi Farm Spa inibição de enzimas
CA2884110A1 (en) * 2012-09-14 2014-03-20 Dow Agrosciences Llc An improved process for the preparation of 2-amino-5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidine from 4-amino-2,5-dimethoxypyrimidine
MX2016002764A (es) 2013-09-05 2016-05-26 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE287262C (enExample) *
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives

Also Published As

Publication number Publication date
CN1254475C (zh) 2006-05-03
RU2298009C2 (ru) 2007-04-27
ES2269772T3 (es) 2007-04-01
CA2462801A1 (en) 2003-04-17
KR100604407B1 (ko) 2006-07-25
KR20040044196A (ko) 2004-05-27
EP1436292A1 (en) 2004-07-14
US20030134873A1 (en) 2003-07-17
JP2005508954A (ja) 2005-04-07
PL370565A1 (en) 2005-05-30
MXPA04003278A (es) 2004-07-23
BR0213177A (pt) 2004-09-14
AU2002338827B2 (en) 2007-09-06
RU2004114277A (ru) 2006-01-10
CN1564821A (zh) 2005-01-12
AR036735A1 (es) 2004-09-29
DE60214408T2 (de) 2007-03-08
EP1436292B1 (en) 2006-08-30
DE60214408D1 (de) 2006-10-12
WO2003031445A1 (en) 2003-04-17
ATE338043T1 (de) 2006-09-15
US6693116B2 (en) 2004-02-17

Similar Documents

Publication Publication Date Title
JP4105089B2 (ja) ８−メトキシ−（１，２，４）トリアゾロ（１，５−ａ）ピリジン誘導体及びそのアデノシンレセプターリガンドとしての使用
JP4216193B2 (ja) ベンゾチアゾール誘導体
JP4216192B2 (ja) アデノシン受容体リガンドとしてのベンゾチアゾール誘導体
AU2002325316A1 (en) Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP4668265B2 (ja) ４−ヒドロキシ−４−メチル−ピペリジン−１−カルボン酸（４−メトキシ−７−モルホリン−４−イル−ベンゾチアゾール−２−イル）−アミド
JP4101756B2 (ja) ５−メトキシ−８−アリール−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン誘導体
JP5202946B2 (ja) ベンゾチアゾール誘導体
AU2002338827A1 (en) Adenosine Receptor Ligands
JP4049672B2 (ja) アデノシン受容体リガンドとしてのアミノトリアゾロピリジン誘導体
JP4101755B2 (ja) ８−アミノ−〔１，２，４〕トリアゾロ〔１，５−ａ〕ピリジン−６−カルボン酸アミド
JP4146799B2 (ja) ベンゾチアゾール誘導体
JP4390772B2 (ja) ベンゾオキサゾール誘導体およびアデノシンレセプターリガンドとしてのその使用
JP2006526003A (ja) ベンゾチアゾール誘導体、およびアデノシンａ２ａ受容体に関連した疾患の処置でのその使用
JP2008506735A (ja) 置換されているベンゾチアゾール類
JP4197649B2 (ja) アデノシン受容体モジュレーターとしてのベンゾチオフェン

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20071121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080319

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110328

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees